Actively Recruiting

Age: 25Years - 65Years
All Genders
Healthy Volunteers
NCT07010705

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Led by University of Rochester · Updated on 2026-01-27

100

Participants Needed

1

Research Sites

66 weeks

Total Duration

On this page

Sponsors

U

University of Rochester

Lead Sponsor

F

Food and Drug Administration (FDA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.

CONDITIONS

Official Title

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Who Can Participate

Age: 25Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age of 25-65 years
  • Genetically confirmed adult-onset Huntington's Disease with CAG ≥ 40 (HD-ISS Stage 2 or mild/moderate Stage 3) for HD participants
  • English speaking
  • Age of 25-65 years for control participants
  • English speaking for control participants
  • Self-identified support person or family member of enrolled HD participants
  • 18 years or older for support persons
  • English speaking for support persons
Not Eligible

You will not qualify if you...

  • Diagnosis of juvenile-onset Huntington's Disease
  • History of co-morbid neurological diseases such as stroke, multiple sclerosis, or moderate to severe traumatic brain injury
  • Use of an assistive device for walking
  • Montreal Cognitive Assessment (MoCA) score of 18 or lower
  • Acute or chronic medical conditions significantly affecting gait or mobility, including ankle sprain or fracture, orthopedic, cardiovascular, or psychiatric diseases
  • Pregnancy
  • Enrollment in a blinded intervention trial at baseline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Rochester Medical Center

Rochester, New York, United States, 14642

Actively Recruiting

Loading map...

Research Team

S

Sugitha Maheswaran, BS

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Digital Measures for Clinical Trial Endpoints in Huntington's Disease | DecenTrialz